- Home
- CUE vs PED Comparison
CUE vs PED Comparison
Compare CUE & PED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUE | PED |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 53.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | PED |
|---|---|---|
| Price | $0.28 | $0.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $3.00 | $1.50 |
| AVG Volume (30 Days) | ★ 1.2M | 154.1K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.43 |
| EPS | N/A | ★ 0.11 |
| Revenue | $7,100,000.00 | ★ $33,244,999.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $305.89 |
| P/E Ratio | ★ N/A | $5.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.43 |
| 52 Week High | $1.75 | $1.00 |
Technical Indicators
Market Signals| Indicator | CUE | PED |
|---|---|---|
| Relative Strength Index (RSI) | 28.27 | 52.89 |
| Support Level | $0.23 | $0.54 |
| Resistance Level | $0.33 | $0.58 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.34 | 55.10 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.